Aligos Therapeutics, Inc.ALGSNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -60.82% | -76.54% | -68.46% | -9.05% | -41.61% |
| Gross Profit Growth | -60.82% | -76.54% | -68.46% | +56.54% | -41.61% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | -413.44% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | -288.89% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | -288.89% | +0.00% |
| Weighted Average Shares Growth | -85.58% | -74.74% | -45.98% | +65.41% | +65.32% |
| Weighted Average Shares Diluted Growth | -85.58% | -74.74% | -44.06% | +65.20% | +65.32% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +3.00% | -53.74% | +17.82% | +23.80% | +24.13% |
| Book Value per Share Growth | +533.71% | +0.00% | +260.49% | -8.40% | -13.27% |
| Debt Growth | -22.42% | -24.81% | -24.90% | -30.08% | -33.59% |
| R&D Expense Growth | +5.72% | -27.97% | -11.39% | -33.76% | +42.70% |
| SG&A Expenses Growth | -28.20% | -19.62% | -24.21% | -3.64% | +11.65% |